Nitric oxide (NO) is implicated in several biological processes, including
cancer progression. At low concentrations, it promotes cell survival and
tumor progression, and at high concentrations it causes apoptosis and cell death. Until now, the impact of NO donors has not been investigated on human endometrial
tumors. Four
cancer cell lines were exposed to different concentrations of
DETA/NO for 24 to 120 h. The effects of
DETA/NO on cell proliferation and invasion were determined utilizing MTS and Boyden chamber assays, respectively. The
DETA/NO induced a dose and time-dependent reduction in cell viability by the activation of
caspase-3 and cell cycle arrest at the G0/G1 phase that was associated with the attenuated expression of cyclin-D1 and D3. Furthermore, the reduction in the amount of CD133-expressing
cancer stem-like cell subpopulation was observed following
DETA/NO treatment of cells, which was associated with a decreased expression of stem cell markers and attenuation of cell invasiveness. To understand the mechanisms by which
DETA/NO elicits anti-
cancer effects,
RNA sequencing (
RNA-seq) was used to ascertain alterations in the transcriptomes of human
endometrial cancer cells.
RNA-seq analysis revealed that 14 of the top 21 differentially expressed genes were upregulated and seven were downregulated in
endometrial cancer cells with
DETA/NO. The genes that were upregulated in all four cell lines with
DETA/NO were the
tumor suppressors Ras association domain family 1
isoform A (RASSF1) and
Cyclin-dependent kinase inhibitor 1A (CDKN1A). The expression patterns of these genes were confirmed by Western blotting. Taken together, the results provide the first evidence in support of the anti-
cancer effects of
DETA/NO in
endometrial cancer.